MAP3K2 and prostate cancer: Breakthroughs in prostate cancer research were able to show MALDI-MSI’s capacity to differentiate malignant tissue from benign tissue through altered distributions of biomarkers such as MEKK2 fragments and phosphatidylinositol, which achieved sensitivities and specificities of more than 85% [212].